Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-F9)

Leinco Technologies
Product Code: LEI-LT7005
Product Group: Primary Antibodies
CodeSizePrice
LEI-LT7005-100ug100 ug£408.00
Quantity:
LEI-LT7005-500ug500 ug£729.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Mouse
Antibody Isotype: Human IgG1
Antibody Clonality: Monoclonal
Antibody Clone: NP1-F9
Regulatory Status: RUO
Target Species:
  • SARS-CoV-2
  • Virus
Application: Enzyme-Linked Immunosorbent Assay (ELISA)
Shipping:
Blue Ice
Storage:
This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Images

1 / 1

Further Information

Antigen Distribution:
The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2.
Concentration:
? 5.0 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Immunogen:
SARS-CoV-2 Nucleocapsid (N) Protein
Long Description:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The N protein is 46 kDa and consists of two highly conserved structural domains, the N-terminal domain (NTD) and C-terminal domain (CTD), connected by a linker region. The NTD and CTD are involved in RNA binding and self-oligomerization, respectively 3, 4. The primary function of the N protein is to bind to and package the viral RNA genome into a helical ribonucleoprotein complex 5. The N protein is also involved in other critical steps of the viral life cycle, including transcription, replication, and modulating infected cell signaling pathways 6, 7. The N protein is abundantly expressed during infection and is highly conserved, sharing 90% amino acid homology with the SARS-CoV N protein 8. It is also immunogenic, and antibodies 8,9 and memory T cells 10, 11 targeting the N protein are present in the sera of convalescent COVID-19 patients, identifying the N protein as a suitable candidate for vaccine development and diagnostic assays. Diagnostic assays based on the N protein effectively detect antibodies in the sera of patients infected with SARS-CoV-2 12. The N protein also contributes to immune evasion by antagonizing antiviral RNAi 13, suggesting its potential value as a targeted therapeutic.
NCBI Gene:
43740575
Purity:
?95% monomer by analytical SEC
Target:
SARS-CoV-2 Nucleocapsid (N)

References

1. Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270?273. 2020. 2. Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265?269. 2020. 3. Kang S, Yang M, Hong Z, et al. Acta Pharm Sin B. 10.1016/j.apsb.2020.04.009. 2020. 4. Chang CK, Sue SC, Yu TH, et al. J Biomed Sci. 13(1):59-72. 2006. 5. Hsieh PK, Chang SC, Huang CC, et al. J Virol. 79(22):13848-13855. 2005. 6. Surjit M, Lal SK. Infect Genet Evol. 8(4):397-405. 2008. 7. Hurst KR, Ye R, Goebel SJ, Jayaraman P, Masters PS. J Virol. 84(19):10276-10288. 2010. 8. Guo L., Ren L., Yang S., et al. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2020. 9. To K.K., Tsang O.T., Leung W.S., et al. Lancet Infect. Dis. 2020.